Dr. Lin is a professor of medicine, she holds joint appointments in the divisions of Hematology and Experimental Pathology and Laboratory Medicine, and is the enterprise leader of cancer regenerative medicine, biotherapeutics, and biomanufacturing at Mayo Clinic. She has been the principal investigator or co-investigator of several clinical trials of chimeric antigen receptor (CAR) T cell therapy, bispecific antibodies, and other novel agents for hematologic malignancies, especially multiple myeloma and lymphoma.